In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Companies Among Top M&A Targets In 2020

Novo Nordisk And Gilead Tipped To Spend

Executive Summary

Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.

You may also be interested in...



A Decade’s Deals In Indian Pharma Point To 2020 Trends

A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.

Horizon Sees Blockbuster Future For Tepezza After US Approval

Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.

Biopharma Leaders Join Trump And Thunberg In Davos

Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates

Topics

Related Companies

UsernamePublicRestriction

Register

IV124415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel